KR102176505B1 - 페닐이미다졸 화합물 - Google Patents

페닐이미다졸 화합물 Download PDF

Info

Publication number
KR102176505B1
KR102176505B1 KR1020187019298A KR20187019298A KR102176505B1 KR 102176505 B1 KR102176505 B1 KR 102176505B1 KR 1020187019298 A KR1020187019298 A KR 1020187019298A KR 20187019298 A KR20187019298 A KR 20187019298A KR 102176505 B1 KR102176505 B1 KR 102176505B1
Authority
KR
South Korea
Prior art keywords
group
substituted
alkyl group
compound
pyridine
Prior art date
Application number
KR1020187019298A
Other languages
English (en)
Korean (ko)
Other versions
KR20180098285A (ko
Inventor
코우시 이와타
타다오 시부타니
사토시 키도
다이스키 모리
히데노리 요시오카
히카루 나카타
아키코 이시마루
Original Assignee
가부시키가이샤 오츠카 세이야쿠 코죠
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 가부시키가이샤 오츠카 세이야쿠 코죠 filed Critical 가부시키가이샤 오츠카 세이야쿠 코죠
Priority to KR1020207026083A priority Critical patent/KR102318395B1/ko
Publication of KR20180098285A publication Critical patent/KR20180098285A/ko
Application granted granted Critical
Publication of KR102176505B1 publication Critical patent/KR102176505B1/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
KR1020187019298A 2015-12-25 2016-10-25 페닐이미다졸 화합물 KR102176505B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020207026083A KR102318395B1 (ko) 2015-12-25 2016-10-25 페닐이미다졸 화합물

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JPJP-P-2015-254016 2015-12-25
JP2015254016 2015-12-25
PCT/JP2016/081633 WO2017110237A1 (ja) 2015-12-25 2016-10-25 フェニルイミダゾール化合物

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020207026083A Division KR102318395B1 (ko) 2015-12-25 2016-10-25 페닐이미다졸 화합물

Publications (2)

Publication Number Publication Date
KR20180098285A KR20180098285A (ko) 2018-09-03
KR102176505B1 true KR102176505B1 (ko) 2020-11-09

Family

ID=59089969

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020207026083A KR102318395B1 (ko) 2015-12-25 2016-10-25 페닐이미다졸 화합물
KR1020187019298A KR102176505B1 (ko) 2015-12-25 2016-10-25 페닐이미다졸 화합물

Family Applications Before (1)

Application Number Title Priority Date Filing Date
KR1020207026083A KR102318395B1 (ko) 2015-12-25 2016-10-25 페닐이미다졸 화합물

Country Status (22)

Country Link
US (1) US10570117B2 (zh)
EP (2) EP3401310B1 (zh)
JP (3) JP6828899B2 (zh)
KR (2) KR102318395B1 (zh)
CN (2) CN108430977B (zh)
AR (2) AR107191A1 (zh)
AU (2) AU2016378154B2 (zh)
CA (1) CA3009485C (zh)
DK (1) DK3401310T3 (zh)
ES (1) ES2913488T3 (zh)
HK (2) HK1257221A1 (zh)
HU (1) HUE058875T2 (zh)
MX (2) MX2018007796A (zh)
MY (1) MY196907A (zh)
PH (1) PH12018501100A1 (zh)
PL (1) PL3401310T3 (zh)
PT (1) PT3401310T (zh)
RU (1) RU2715712C2 (zh)
SG (1) SG11201804310VA (zh)
TW (2) TWI780557B (zh)
WO (1) WO2017110237A1 (zh)
ZA (1) ZA201803419B (zh)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4190329A1 (en) * 2020-07-30 2023-06-07 Otsuka Pharmaceutical Factory, Inc. Cold remedy and antiviral agent

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4134983A (en) * 1975-03-03 1979-01-16 Merck & Co., Inc. 3-amino-2-or-propoxyaryl substituted imidazoles
US4642311A (en) * 1975-03-03 1987-02-10 Merck & Co., Inc. β-adrenergic blocking imidazolylphenoxy propanolamines
CA1075689A (en) * 1976-07-23 1980-04-15 John J. Baldwin Substituted imidazoles, their preparation and use
AU518569B2 (en) 1979-08-07 1981-10-08 Farmos-Yhtyma Oy 4-benzyl- and 4-benzoyl imidazole derivatives
US4443446A (en) 1980-05-30 1984-04-17 University Of Georgia Research Foundation, Inc. Use of psychoactive drugs as vaginal contraceptives
US5861359A (en) * 1995-07-25 1999-01-19 Fmc Corporation Herbicidal phenylmethoxphenyl heterocycles
DK2280706T3 (da) * 2008-05-14 2013-02-04 Otsuka Pharma Co Ltd Lipasa-aktiverende lipoproteinsammensætninger omfattende benzenderivater
TWI435871B (zh) * 2009-02-04 2014-05-01 Otsuka Pharma Co Ltd 苯基咪唑化合物
EP3293177A4 (en) * 2015-04-07 2018-12-12 Guangdong Zhongsheng Pharmaceutical Co., Ltd Tyrosine kinase inhibitor and pharmaceutical composition comprising same

Also Published As

Publication number Publication date
HK1257353A1 (zh) 2019-10-18
SG11201804310VA (en) 2018-06-28
AR123029A2 (es) 2022-10-26
AU2016378154B2 (en) 2020-08-13
TW201722937A (zh) 2017-07-01
EP4023640A1 (en) 2022-07-06
PH12018501100A1 (en) 2019-01-28
HUE058875T2 (hu) 2022-09-28
JPWO2017110237A1 (ja) 2018-10-11
TWI780557B (zh) 2022-10-11
AU2016378154A1 (en) 2018-06-07
EP3401310B1 (en) 2022-04-06
JP2021042250A (ja) 2021-03-18
ES2913488T3 (es) 2022-06-02
HK1257221A1 (zh) 2019-10-18
RU2020105627A3 (zh) 2022-02-22
KR20200108118A (ko) 2020-09-16
ZA201803419B (en) 2019-08-28
CN108430977A (zh) 2018-08-21
AU2020260426A1 (en) 2020-11-26
AU2020260426B2 (en) 2021-10-07
KR20180098285A (ko) 2018-09-03
MX2018007796A (es) 2019-05-23
MX2021010182A (es) 2022-10-25
DK3401310T3 (da) 2022-05-02
CN108430977B (zh) 2021-06-08
RU2018127016A (ru) 2020-01-30
PT3401310T (pt) 2022-06-02
US10570117B2 (en) 2020-02-25
BR112018012326A2 (pt) 2018-12-04
US20180354930A1 (en) 2018-12-13
KR102318395B1 (ko) 2021-10-27
CA3009485C (en) 2020-08-25
PL3401310T3 (pl) 2022-07-04
EP3401310A1 (en) 2018-11-14
JP2023017055A (ja) 2023-02-02
CA3009485A1 (en) 2017-06-29
JP6828899B2 (ja) 2021-02-10
JP7224674B2 (ja) 2023-02-20
MY196907A (en) 2023-05-09
RU2020105627A (ru) 2020-02-17
EP3401310A4 (en) 2019-05-29
AR107191A1 (es) 2018-03-28
TWI721057B (zh) 2021-03-11
TW202124376A (zh) 2021-07-01
RU2018127016A3 (zh) 2020-01-30
WO2017110237A1 (ja) 2017-06-29
CN113200962A (zh) 2021-08-03
RU2715712C2 (ru) 2020-03-03

Similar Documents

Publication Publication Date Title
US11001579B2 (en) Ferroportin inhibitors
EP1458383B1 (en) Heteroaryl substituted pyrazole modulators of metabotropic glutamate receptor-5
EP1434773B1 (en) Heteroaryl substituted tetrazole modulators of metabotropic glutamate receptor-5
JP6955482B2 (ja) Ｔｎｆアルファの修飾因子として有用なヘテロ環化合物
AU2018202148B2 (en) Substituted pyridine and pyrazine compounds as PDE4 inhibitors
KR101819433B1 (ko) 인돌린-2-온 또는 피롤로-피리딘-2-온 유도체
JP2022518860A (ja) 免疫調節剤、組成物およびその使用方法
CN110156770B (zh) 作为tam族激酶抑制剂的氨基吡啶衍生物
WO2014062667A1 (en) Phenyl linked quinolinyl modulators of ror-gamma-t
KR20130133051A (ko) 6,5-헤테로사이클릭 프로파길릭 알콜 화합물 및 이의 용도
US7268151B2 (en) Di-aryl substituted triazole modulators of metabotropic glutamate receptor-5
KR20130062951A (ko) 키누레닌 생성 억제 작용을 갖는 함질소 복소환 화합물
WO2013052395A1 (en) 1,3-substituted azetidine pde10 inhibitors
KR20180107232A (ko) 오렉신 수용체 조정제로서의 할로-치환된 피페리딘
JP2023017055A (ja) フェニルイミダゾール化合物
BR112018012326B1 (pt) Compostos de fenilimidazol, composiçâo farmacêutica e ativador de lpl compreendendo o referido composto e seu uso

Legal Events

Date Code Title Description
A201 Request for examination
AMND Amendment
E902 Notification of reason for refusal
AMND Amendment
E601 Decision to refuse application
A107 Divisional application of patent
AMND Amendment
X701 Decision to grant (after re-examination)
GRNT Written decision to grant